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UNLABELED AND INVESTIGATIONAL USAGE
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. Restoration of function through optimal healing is the main goal when treating open fractures and prevention of infection by the use of antibiotic prophylaxis and wound debridement are critical to achieving this goal. The benefi t of antibiotic prophylaxis in this setting has long been established. [4] [5] [6] The regimen of prophylaxis should not be directed at all organisms isolated from a contaminated fracture site; rather it should be directed against the most relevant pathogens causing surgical site infection. Thus, the purpose of this review is to analyze the evidence behind the current recommendations for antibiotic prophylaxis in the management of open fractures and the changing epidemiology of Staphylococcus aureus, the most common cause of surgical site infection after open fractures.
DATA SOURCES
We performed a computerized bibliographic search using the databases We also reviewed the reference list of relevant trials retrieved by our electronic search.
We used the United States Preventive Services Task Force to stratify the quality of evidence. For the purpose of this review, 7 studies eligible as Level-I evidence were analyzed for antibiotic selection, timing and duration for prophylaxis in open fractures (Table) . Studies with Level I and II evidence were selected for the epidemiology of S aureus in trauma patients. Thirteen articles were reviewed and referred to as evidence for the emergence of MRSA in orthopedic trauma patients.
DATA SUPPORTING CURRENT PROPHYLAXIS RECOMMENDATIONS Antibiotic Selection
In 1974, Patzakis et al 6 demonstrated a reduction of infections in patients with open fracture wounds who received prophylactic antibiotics. Cephalothin, a fi rst generation antibiotic, was demonstrated to be superior to both no antibiotics and to a regimen of penicillin and streptomycin. The superiority of cephalothin was attributed to its activity against S aureus, the organism most often implicated as a cause of infection in open fractures, and generally resistant to penicillin and streptomycin. Although the penicillin and streptomycin regimen had broader coverage against gram negative and anaerobes when compared to cephalothin, the dual regimen did not differ signifi cantly in preventing infections when compared to the placebo group. Thus the authors concluded that "antibiotics expected to be effective against coagulase-positive S aureus should be selected for prophylactic therapy of open fractures caused by direct trauma."
In agreement with the fi ndings of Patzakis et al, 6 two randomized, controlled trials corroborate the benefi t of prophylactic antibiotics directed against S aureus in the management of open fractures. Bergman, 5 in 1982, demonstrated a signifi cant decrease in both superfi cial and deep wound infection in open fractures with severe soft tissue injury with the administration of perioperative dicloxacillin compared with placebo. Subsequently, a similar trial by Braun et al 4 confi rmed the benefi t of using prophylactic cloxacillin against placebo for prevention of infection in open fracture wounds. A consistent fi nding of these studies was the need for prophylaxis with agents that have activity against gram positive organisms and specifi cally S aureus, which accounts for 50% of surgical site infections after open fractures.
2,4-6 It should be noted that both dicloxacillin and cloxacillin have a narrow spectrum of activity directed exclusively at S aureus and some species of aerobic and anaerobic streptococci, and with no activity against gram negative organisms or obligate anaerobes.
Despite the evidence supporting systemic prophylactic antibiotics after open fractures active against S aureus, data demonstrating the optimal antistaphylococcal regimen is lacking. The current quality standard for the management of open fractures includes the administration of parenteral antibiotic prophylaxis with an effective regimen consisting of a fi rst generation cephalosporin, usually cefazolin. 7, 8 This is a class IA recommendation implying that this intervention is effective with evidence derived from multiple randomized clinical trials. However, since these studies were conducted, the epidemiology of gram positive organisms causing surgical site infection has changed. All these landmark studies were accomplished before the widespread emergence cme ARTICLE of MRSA as a cause of infection in patients with open fractures. 9, 10 Methicillin resistance among S aureus is now widespread in both hospital and community settings. 10, 11 Yet, guidelines still promote antibiotics that cover a decreasing proportion of S aureus, those that remain susceptible to methicillin. 7, 8 Conversely, the role of gram negative rods and the need for prophylaxis against these organisms has not been established. Bergman described gram negative infections as "infrequent and healed without supplementary treatment with systemic antibiotics."
5 Two placebo-controlled trials reported a rate of gram negative surgical site infection between 9.6 to 14.2, most of them caused by pseudomonas species that are not within cefazolin's spectrum of activity. 4, 5 In a 1999 double-blind controlled trial by Carsenti-Etesse et al, 616 patients with open tibial fracture requiring open reduction and internal fi xation were randomized to receive pefl oxacin versus cefazolin after their fracture and assessed for surgical site infection within 3 months. 12 Although pefl oxacin has activity against pseudomonas species and overall a broader spectrum of gram negative coverage than cefazolin, there was no difference in surgical site infection rates between the 2 groups (7% vs 8%, respectively, Pϭ.51). Finally, it should be noted that vancomycin, an antibiotic with no activity against gram negative rods, is recommended for the antibiotic prophylaxis of open fractures in beta-lactam allergic patients without the addition of a second agent with gram negative activity. 8 The most recent evidence-based systemic review to defi ne the Surgical Infections Society guidelines on prophylactic antibiotic use in open fractures concluded that there is insuffi cient data on gram negative prophylaxis to justify such coverage. 7 Despite the lack of evidence, a recent survey answered by 74 program directors from academic orthopedic resi- 13 Therefore, the benefi ts of adding gram negative prophylaxis in specifi c fracture types and its impact on antibiotics resistance remain to be determined by future investigations.
Timing and Duration of Prophylactic Antibiotics
The goal of antibiotic prophylaxis in open fractures is to achieve adequate tissue levels as soon as possible following the injury. Patzakis and Wilkins 14 demonstrated a clear benefi t if antibiotics are given within 3 hours after the injury with a rate of infection of 4.7% compared with a rate of 7.4% if antibiotics were delayed for Ͼ3 hours.
Conversely, the duration of prophylactic treatment is not well established and remains a topic of discussion. Many authors advocate the use of prophylaxis for 3 days. 15, 16 However, a prospective, doubleblind, randomized controlled trial showed that antibiotics administered for 24 hours were not inferior to a prolonged course for prevention of fracture site infections. 17 In addition, the duration of prophylactic antibiotic regimens is directly related to the probability of developing resistant microorganisms. 18 As a result, the current guidelines recommend the administration of prophylactic antibiotics within 3 hours of the injury until 24 hours after the surgical intervention. 7, 8 Additional prophylaxis for 24 hours is recommended for subsequent interventions in the same surgical area.
EMERGENCE OF MRSA AS A CAUSE OF INFECTION AFTER OPEN FRACTURES
Previous studies have shown that 37% of healthy people are carriers of S aureus on their anterior nares and skin, and this carriage predispose them to a higher risk of S aureus surgical site infection. 19 Shukla et al 20 screened for MRSA colonization 2473 adult patients admitted to a trauma ward in England. They found that the rate of MRSA surgical site infection was signifi cantly higher for MRSA carriers compared to those not colonized (8.8% vs 2.3%, PϽ.001). They concluded that MRSA carriers have a 2.5-times higher risk than that of the normal population of developing postoperative MRSA surgical site infection.
Beginning in 2003, major cities in the United States have experienced increasing rates of MRSA colonization and infection originating in the community. 11, 21 This "community-acquired" strain, frequent in patients without the classic risk factors, has similar virulence, 22 resistance, and limited treatment options as those originating in the hospital. 21 Reported MRSA colonization rates in trauma patients have been higher than expected (10.44%) 23 compared to the prevalence in general orthopedic patients (4%-5.6%). 24, 25 This fi nding parallels the increase in MRSA surgical site infections after fracture fi xation in both elective and acute trauma patients 9, 20, 26 representing a challenge to clinicians knowing its associated increased morbidity and restricted therapeutic options.
Carsenti-Etesse et al 12 fi rst described the emergence of hospital-acquired MRSA as well as methicillin-resistant coagulase negative staphylococci as a cause of infection after open fractures and the concerns for broader prophylactic coverage against these organisms. They evaluated the bacteriology of infections in open leg fracture wounds and confi rmed that S aureus accounts for the majority (37%) of these, with almost a third of them caused by MRSA.
Recently, in an effort to determine the contemporary microbiology of surgical site infection in open fractures, Johnson et al 26 characterized the infections seen in conjunction with combat-associated type III tibial fractures. In this case series, 35 patients wounded in Iraq or Afghanistan who received prophylactic cefazolin and surgical debridement for an open fracture were analyzed. In all, 13 patients developed infection and delayed union. Surgical cultures taken from the delayed union site revealed S aureus in 69% of the cases (9 of 13 patients) with more than a third (4 of 13) due to MRSA. Although this study does not allow the authors to make recommendations on antibiotic prophylaxis, they emphasize the need for further investigations on this topic.
In an attempt to address the increasing prevalence of MRSA surgical site infection, a randomized controlled trial performed in elective orthopedic patients concluded that glycopeptides such as teicoplanin ensure adequate surgical prophylaxis comparable to cefazolin in this setting. 27 Additionally, a quasi-experimental cohort study performed in Europe demonstrated signifi cantly reduced rates of MRSA surgical site infection (2.73 vs 0.19, PϽ.005) in elective orthopedic patients by adding high dose teicoplanin to the standard antibiotic prophylaxis regimen. 28 Most recently in 2008, the Society for Healthcare Epidemiology of America in collaboration with Infectious Diseases Society of America published their recommendations to prevent surgical site infection in acute care hospitals. They highlighted the importance of prophylaxis against MRSA in specifi c clinical circumstances and the need for prospective trials looking at the addition of a glycopeptide to standard antibiotic prophylaxis. 29 Once infection with MRSA occurs, cure is diffi cult. Staphylococcus aureus have a propensity to cause bone and joint infections and seem to have the ability to persist in a latent state and cause recrudescent infections after decades. 30 This organism expresses several factors that compromise the effectiveness of neutrophils and macrophages, the fi rst line of defense against infections. 31 In addition, S aureus can survive in phagosomes, and express polysaccharides and proteins that inhibit opsonization by antibodies and complement. These characteristics make treatment of even methicillin susceptible strains of S aureus challenging, and the added factor of methicillin resistance poses even more challenges due to limited and perhaps suboptimal treatment options.
Treatment involves prolonged courses of antibiotic with activity against MRSA; however, the organisms cannot be eradicated completely with this regimen until radical debridement, including hardware removal, is performed. 32 This may not be possible in many cases until fracture union is complete leading to either infection relapses or chronic suppression with prolonged courses of oral antibiotics.
Johnson and Johnston 9 reported a case series of 38 patients with MRSA infection related to their orthopedic intervention site during a hospital outbreak. The majority (84%) had surgical debridement and stabilization of a fracture with subsequent surgical site infection. They found that orthopedic infections due to MRSA carry extreme morbidity as a result of prolonged hospitalization, increased number of surgical procedures per patient, higher amputation rates, loss of musculoskeletal function, and extreme cost for both medical care and time lost from productive employment. In addition, studies assessing adverse outcomes associated with MRSA surgical site infections compared to those with methicillin sensitive strains found greater 90-day mortality rate, 1.19-fold increase in hospital costs, 33 and increased mortality at 12 months. 20 Considering the detrimental consequences of MRSA in musculoskeletal surgical site infections, the local prevalence of MRSA and specifi c risk factors are likely to be important variables in the choice of a prophylactic strategy in open fractures.
CONCLUSION
Antibiotic selection for prophylaxis in open fractures should be infl uenced by organism most often implicated as a cause of infection and by the relative cost and availability of the agents. Staphylococcus aureus is the most common organism causing surgical site infection in this setting and in agreement with previous studies it should be the main target of prophylaxis. However, the epidemiology of this organism has changed and methicillin sensitive strains are being replaced by those methicillin resistant. In addition, MRSA, thought to be a hospital-acquired organism, is now originating in the community. Despite the fact that trauma patients come from the community and do not have the usual risk factors for MRSA acquisition, the number of MRSA infection in this population is dramatically increasing leading to signifi cant morbidity and higher hospital costs.
Considering the increasing rates of MRSA infection after open fractures, a large multicenter study should be initiated to determine the epidemiology of S aureus in trauma patients and whether targeted MRSA prophylaxis should be recommended for such patients. In the meantime, we recommend that providers consider selecting antibiotics active against MRSA for open fracture prophylaxis based on the local prevalence of MRSA carriage, surgical site infection rates and individualized risks factors.
